{"id":"l-ornithine-l-aspartate","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":null,"effect":"Hyperammonemia (paradoxical, rare)"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL516169","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug provides substrates (ornithine and aspartate) that stimulate the urea cycle and increase ammonia clearance through enhanced glutamine formation in muscle and liver. By reducing circulating ammonia levels, it alleviates the neurological symptoms associated with hepatic encephalopathy, particularly in patients with chronic liver disease or portal hypertension.","oneSentence":"L-ornithine L-aspartate enhances ammonia detoxification by promoting urea cycle function and glutamine synthesis in hepatic encephalopathy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:17.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatic encephalopathy (acute and chronic)"},{"name":"Portal-systemic encephalopathy"}]},"trialDetails":[{"nctId":"NCT05042245","phase":"PHASE4","title":"The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2019-07-23","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":237},{"nctId":"NCT07117630","phase":"PHASE2","title":"An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-25","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Overt Hepatic Encephalopathy","enrollment":174},{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":"Overt Hepatic Encephalopathy","enrollment":252},{"nctId":"NCT05737030","phase":"PHASE4","title":"Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Graz","startDate":"2023-02-06","conditions":"Cirrhosis","enrollment":55},{"nctId":"NCT05539027","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-09-20","conditions":"Hepatic Encephalopathy","enrollment":140},{"nctId":"NCT05920213","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2023-10","conditions":"Hepatic Encephalopathy Stage 2, Hepatic Encephalopathy Stage 3, Hepatic Encephalopathy Stage 4","enrollment":360},{"nctId":"NCT05778461","phase":"NA","title":"Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-03-15","conditions":"Liver Failure, Acute","enrollment":32},{"nctId":"NCT03577938","phase":"NA","title":"Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment","status":"COMPLETED","sponsor":"Beijing 302 Hospital","startDate":"2019-01-10","conditions":"Acute on Chronic Liver Failure, Traditional Chinese Medicine, Hepatitis B","enrollment":516},{"nctId":"NCT05042024","phase":"PHASE3","title":"Supplementation With L-ornithine But Not L-arginine Increases Density of CD68+ and CD163+ Macrophages in Periodontitis","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2017-10-20","conditions":"Periodontitis","enrollment":75},{"nctId":"NCT01041755","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Centro Regional para el Estudio de las Enfermedades Digestivas","startDate":"2009-11","conditions":"Hepatic Encephalopathy","enrollment":30},{"nctId":"NCT00740142","phase":"PHASE4","title":"Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-09","conditions":"Hepatic Encephalopathy","enrollment":35},{"nctId":"NCT02158182","phase":"PHASE4","title":"Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding","status":"COMPLETED","sponsor":"Hospital General de Mexico","startDate":"2014-07","conditions":"Hepatic Encephalopathy","enrollment":88},{"nctId":"NCT01722578","phase":"PHASE4","title":"L-ornithine L-aspartate in Overt Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Dayanand Medical College and Hospital","startDate":"2013-12","conditions":"Cirrhosis of Liver, Hepatic Encephalopathy","enrollment":200},{"nctId":"NCT01847651","phase":"PHASE4","title":"Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-08","conditions":"Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Cirrhosis","enrollment":42},{"nctId":"NCT00305591","phase":"NA","title":"Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2006-03","conditions":"Cirrhosis, Hepatic Encephalopathy","enrollment":50},{"nctId":"NCT01440829","phase":"PHASE2, PHASE3","title":"The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2011-12","conditions":"Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices","enrollment":40},{"nctId":"NCT00896831","phase":"PHASE4","title":"Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2008-11","conditions":"Hepatic Encephalopathy","enrollment":96},{"nctId":"NCT00470314","phase":"PHASE2","title":"Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2005-01","conditions":"Acute Liver Failure","enrollment":150},{"nctId":"NCT00433368","phase":"PHASE3","title":"Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2003-10","conditions":"Hepatic Encephalopathy","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":179,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hepa-Merz","Hepamerz"],"phase":"marketed","status":"active","brandName":"L-ornithine L-aspartate","genericName":"L-ornithine L-aspartate","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-ornithine L-aspartate enhances ammonia detoxification by promoting urea cycle function and glutamine synthesis in hepatic encephalopathy. Used for Hepatic encephalopathy (acute and chronic), Portal-systemic encephalopathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}